4 active not recruiting. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 4 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Fibrosarcoma: new trials by email Literature Review of Fibrosarcoma trials Research Report on Fibrosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| Tazemetostat in Malignant Peripheral Nerve Sheath Tumors Tazemetostat - Peripheral Nerve Sheath Tumor | Phase 2 | Active not recruiting | University of Florida | 10 | 2021-08-25 | 2026-06-04 |
| A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors Phase 1b: APG-115+pembrolizumab - Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma | Phase 1 / Phase 2 | Active not recruiting | Ascentage Pharma Group Inc. | 230 | 2018-08-29 | 2025-08-07 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
Neurofibrosarcoma (4) · Carcinoma, Adenoid Cystic (2) · Carcinosarcoma (2) · Cholangiocarcinoma (2) · Gallbladder Neoplasms (2) · Hemangiosarcoma (2) · Parathyroid Neoplasms (2) · Sarcoma (2) · Thyroid Neoplasms (2) · Vulvar Neoplasms (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adenocarcinoma, Mucinous (1) · Adrenal Gland Neoplasms (1) · Adrenocortical Carcinoma (1) · Anus Neoplasms (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Connective Tissue (4) · Neoplasms, Connective and Soft Tissue (4) · Neoplasms, Fibrous Tissue (4) · Neoplasms, Nerve Tissue (4) · Nervous System Diseases (4) · Nervous System Neoplasms (4) · Neurofibroma (4) · Neuromuscular Diseases (4) · Peripheral Nervous System Diseases (4) · Peripheral Nervous System Neoplasms (4) · Neoplasms by Site (3) · Neoplasms, Germ Cell and Embryonal (3)
Nivolumab (2) · CTLA-4 Antigen (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · pembrolizumab (1) · tazemetostat (1)
Ascentage Pharma Group Inc. (1) · Instituto do Cancer do Estado de São Paulo (1) · National Cancer Institute (NCI) (1) · University of Florida (1)
United States (3) · Australia (1) · Brazil (1) · Guam (1)
Camila MV Moniz, Doctor (1) · Joanne Lagmay, MD (1) · Sandip P Patel (1) · Yifan Zhai, MD, PhD (1)
PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
U10CA180888 (1)